首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1516078

心臟病學和神經病學市場的IVD - 按產品類型（儀器、試劑、試劑盒和消耗品、軟體和服務）、技術（免疫測定、分子診斷、血液學）、最終用途（醫院、診所） - 全球預測（2024 年- 2032 年）

IVD in Cardiology and Neurology Market - By Product Type (Instruments, Reagents, Kits & Consumables, Software & Services), Technology (Immunoassays, Molecular Diagnostics, Hematology), End-use (Hospitals, Clinics) - Global Forecast (2024 - 2032)

出版日期: 2024年04月03日 | 出版商:

Global Market Insights Inc. | 英文 176 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於心血管和神經系統疾病盛行率不斷上升，預計 2024 年至 2032 年間，心臟病學和神經病學領域的 IVD 市場規模複合年成長率將達到 5%。根據世界衛生組織的數據，心血管疾病 (CVD) 是全球主要死亡原因，每年奪走約 1,790 萬人的生命。由於心臟病和中風仍然是死亡的主要原因，對早期準確診斷工具的需求不斷增加。生物標記、分子診斷和即時檢測等 IVD 技術為及時檢測、監測和管理這些病症提供了關鍵資訊。

快速的技術創新和不斷增加的醫療支出也將影響市場的成長。新一代定序、數位病理學和基於人工智慧的診斷工具等新診斷平台的開發將提高測試的準確性和有效性，使其在臨床環境中不可或缺。對醫療保健基礎設施的投資，特別是對新興經濟體的投資，也將改善獲得先進診斷服務的機會，從而擴大市場成長。

心臟病學和神經病學行業的 IVD 按產品類型、技術、最終用途和地區細分。

根據產品類型，軟體和服務領域的市場佔有率預計到 2032 年將產生可觀的收入，這有利於其準確性、效率和診斷程序的整合。先進的軟體可以分析複雜的診斷資料，從而做出準確、及時的患者護理決策，同時實現程序自動化並提高效率。資料管理、遠端監控和遠距醫療等服務也變得越來越重要，特別是由於慢性心血管和神經系統疾病的流行。

由於對血液相關參數提供重要見解的強烈需求，血液學技術領域的心臟病學和神經病學行業的 IVD 預計將在 2024 年至 2032 年期間出現可觀的成長。全血球計數 (CBC) 和凝血譜等血液學檢查有助於檢測貧血、凝血障礙以及可能嚴重影響心臟和大腦健康的疾病等狀況。這些測試對於評估風險因素、檢查疾病進展和評估治療措施的有效性也很重要。

由於神經系統和心血管疾病的負擔日益增加，預計亞太地區心臟病學和神經系統疾病的 IVD 行業將在 2024 年至 2032 年期間以適度的速度成長。快速的城市化和生活方式的改變導致中風、失智症和冠心病等疾病的發病率激增，進一步增加了對先進診斷解決方案的需求。該地區多個政府也大力投資衛生基礎設施，並透過公共衛生措施促進早期診斷，刺激了該地區市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 心血管和神經系統疾病的盛行率不斷上升
  - IVD 診斷技術的進步
  - 照護端測驗的採用率不斷上升
  - 日益關注新型診斷方法開發的研究
- 產業陷阱與挑戰
  - 嚴格的監管場景
  - 開發成本高
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按產品類型，2021 - 2032 年

主要趨勢
儀器
試劑、試劑盒和消耗品
軟體與服務

第 6 章：市場估計與預測：按技術分類，2021 - 2032 年

主要趨勢
免疫測定
- 酵素連結免疫吸附測定法 (ELISA)
- 化學發光免疫分析 (CLIA)
- 螢光免疫分析 (FIA)
- 其他免疫測定
分子診斷
- 聚合酶鍊式反應 (PCR)
- 雜交
- 定序
- 等溫核酸擴增技術（INAAT）
- 微陣列
- 其他分子診斷
血液學
其他技術

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院和診所
診斷實驗室
其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abbott Laboratories
Becton, Dickinson and Company
bioMerieux S.A.
Bio-Rad Laboratories, Inc.
Danaher Corporation
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd.
QIAGEN N.V.
Siemens Healthineers AG
Sysmex Corporation
Thermo Fisher Scientific Inc.

簡介目錄

Product Code: 8846

IVD in cardiology and neurology market size is projected to record 5% CAGR between 2024 and 2032, driven by the rising prevalence of cardiovascular and neurological diseases. As per WHO, cardiovascular diseases (CVDs) are the major cause of death worldwide, claiming around 17.9 million lives every year. As heart diseases and strokes continue to be the leading causes of death, the demand for early and accurate diagnostic tools is increasing. IVD technologies, such as biomarkers, molecular diagnostics, and point-of-care testing provide critical information for the timely detection, monitoring, and management of these conditions.

Rapid technological innovations and increasing healthcare expenditures will also influence the market growth. The development of new diagnostic platforms, such as next-generation sequencing, digital pathology, and AI-based diagnostic tools will improve the accuracy and efficacy of tests, making them indispensable in clinical settings. Investments in healthcare infrastructure, specifically in emerging economies, will also improve access to advanced diagnostic services, expanding the market growth.

The IVD in cardiology and neurology industry is segmented into product type, technology, end-use and region.

Based on product type, the market share from the software & services segment is poised to generate substantial revenue by 2032, favored their accuracy, efficiency, and integration of diagnostic procedures. Advanced software enables analysis of complex diagnostic data for accurate and timely patient care decisions while automating procedures and improving efficiency. Services, such as data management, remote monitoring and telemedicine are also becoming increasingly important, especially due to the prevalence of chronic cardiovascular and neurological diseases.

IVD in cardiology and neurology industry from the hematology technology segment is slated to witness decent growth during 2024-2032, led by the strong need for providing crucial insights into blood-related parameters. Hematology tests, such as complete blood count (CBC) and coagulation profiles help detect conditions like anemia, clotting disorders, and diseases that can seriously affect heart and brain health. These tests are also important to assess risk factors, examine the progression of the disease and estimate the effectiveness of treatment measures.

Asia Pacific IVD in cardiology and neurology industry is anticipated to expand at a modest rate over 2024-2032, attributed to the increasing burden of neurological and cardiovascular diseases. Rapid urbanization and lifestyle changes have surged the incidence of diseases, such as strokes, dementia, and coronary heart disease, further increasing the demand for advanced diagnostic solutions. Multiple governments in the region are also investing significantly in health infrastructure and promoting early diagnosis through public health initiatives, stimulating the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of cardiovascular and neurological disorders
  - 3.2.1.2 Technological advancements in IVD diagnostics
  - 3.2.1.3 Rising adoption of point of care testing
  - 3.2.1.4 Increasing focus on research for the development of novel diagnostics
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High development costs
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
5.3 Reagents, kits, & consumables
5.4 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Immunoassays
- 6.2.1 Enzyme-linked immunosorbent assay (ELISA)
- 6.2.2 Chemiluminescence immunoassay (CLIA)
- 6.2.3 Fluorescence immunoassay (FIA)
- 6.2.4 Other immunoassays
6.3 Molecular diagnostics
- 6.3.1 Polymerase chain reaction (PCR)
- 6.3.2 Hybridization
- 6.3.3 Sequencing
- 6.3.4 Isothermal nucleic acid amplification technology (INAAT)
- 6.3.5 Microarrays
- 6.3.6 Other molecular diagnostics
6.4 Hematology
6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals & clinics
7.3 Diagnostic laboratories
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa